Hagens Berman Alerts American Renal Associates Holdings, Inc. (ARA) Investors of Investigation of Admitted Improper Accounting and Financial Restatements

SAN FRANCISCO, March 28, 2019 /PRNewswire/ — Hagens Berman Sobol Shapiro LLP alerts investors in American Renal Associates Holdings, Inc. (NYSE: ARA) of the firm’s investigation of possible violations of the Federal securities laws.  If you purchased or otherwise acquired American Renal securities before March 28, 2019 and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information about the investigation click

https://www.hbsslaw.com/cases/ARA

or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing

mailto:ARA@hbsslaw.com.

On March 8, 2019, American Renal and senior management announced they would not timely file the Company’s annual report for the fiscal year ended December 31, 2018.

On March 27, 2019, they announced investors should not rely on the Company’s previously issued consolidated financial statements for the fiscal years ended December 31, 2014, 2015, 2016 and 2017 or on several interim quarterly period financial statements.

Among other things, American Renal and senior management announced they overstated revenue and would restate the Company’s financial statements.

In addition, the Company’s Chief Financial Officer (Jason Boucher) abruptly resigned effective March 26, 2019.

Since March 7, 2019, the price of American Renal shares has fallen as much as $6.69, or down over 50%.

“We’re focused on investors’ losses, the admitted improper revenue accounting that might have been intentional, and the extent to which investors may have been misled,” said Hagens Berman partner Reed Kathrein.

Whistleblowers:  Persons with non-public information regarding ARA should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email mailto:ARA@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 78 attorneys in 9 offices across the country.  The firm represents investors, whistleblowers, workers and consumers in complex litigation.  More about the firm and its successes can be found at www.hbsslaw.com.  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 510-725-3000

SOURCE Hagens Berman Sobol Shapiro LLP

Related Links

https://www.hbsslaw.com

WHAT TO READ NEXT...
Netcompany Group A/S – Launch of share buyback programme

Company announcement No. 9/2021                                                                                                              6 May 2021 Launch of share buyback programmeToday, Netcompany Group A/S (“Netcompany”) announces that the Board of Directors has decided

Targovax ASA: First quarter 2021 results

OSLO, Norway, May 6, 2021 /PRNewswire/ — Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today

Athenex 收購 Kuur Therapeutics,以透過現成工程的 CAR-NKT 平台擴大細胞療法的開發

革命性的領先 NKT 細胞轉化平台技術擴展了 Athenex 細胞療法的開發能力 NKT 細胞轉導使該平台用途廣泛,因其具有嵌合抗原受體 (CAR) 和 T 細胞受體 (TCR) ,分別針對血液學和實體癌症 潛在總代價為 1.85 億美元,其中包括 7,000 萬美元的預付款(主要是 Athenex 普通股)和 1.15 億美元的開發里程碑 紐約水牛城, May 06,

Initiation of new share buyback program

Based on the continued solid business performance and GN’s capital structure policy, and in accordance with the authorization granted to the Board of Directors at